Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing-remitting multiple sclerosis

about

Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing-remitting multiple sclerosis

Item

http://www.wikidata.org/entity/Q57039929

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Peginterferon β-1a every 2 wee ...... g-remitting multiple sclerosis

@en

Peginterferon β-1a every 2 wee ...... g-remitting multiple sclerosis

@nl

type

Item

label

Peginterferon β-1a every 2 wee ...... g-remitting multiple sclerosis

@en

Peginterferon β-1a every 2 wee ...... g-remitting multiple sclerosis

@nl

prefLabel

Peginterferon β-1a every 2 wee ...... g-remitting multiple sclerosis

@en

Peginterferon β-1a every 2 wee ...... g-remitting multiple sclerosis

@nl

P1476

Peginterferon β-1a every 2 wee ...... g-remitting multiple sclerosis

@en

P2093

Douglas L Arnold

http://www.w3.org/2001/XMLSchema#string

Maria L Naylor

http://www.w3.org/2001/XMLSchema#string

Matthias Meergans

http://www.w3.org/2001/XMLSchema#string

Qunming Dong

http://www.w3.org/2001/XMLSchema#string

Shulian Shang

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Is it time to target no evident disease activity (NEDA) in multiple sclerosis?

The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics.

Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.

Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.

Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.

Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE

Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.

Long-term evolution of multiple sclerosis disability in the treatment era.

Defining high, medium and low impact prognostic factors for developing multiple sclerosis.

P304

1756286418795085

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1756286418795085

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30181780

http://www.w3.org/2001/XMLSchema#string

P921

Farmakologi

relapsing-remitting multiple sclerosis

P932

6113732

http://www.w3.org/2001/XMLSchema#string